

**MEDICATION SECTION**  
**IPRATROPIUM BROMIDE**

Initial Date: 07/19/2023  
Revised Date: 08/11/2023

---

***Ipratropium Bromide***

**Pharmacological Category:** Anticholinergic Agent

**Routes:** Nebulized

**Indications:**

1. Wheezing
2. Airway Constriction

**Contraindications:**

1. Hypersensitivity to atropine or its derivatives

**Expected effects:**

1. Decreased wheezing
2. Decreased respiratory distress

**Notes:** May be administered in conjunction with albuterol 2.5 mg/3 mL NS as a 'Duoneb'.

**Side effects:**

1. Palpitations
2. Dry Mouth
3. Anxiety

**Dosing: ANAPHYLAXIS ALLERGIC REACTION**

Indication: Continued wheezing and/or airway constriction after administration of nebulized albuterol.

Adults and pediatrics administer:

1. Ipratropium 500 mcg/2.5 mL NS nebulized

**Dosing: ADULT RESPIRATORY DISTRESS**

Indication: Continued wheezing and/or airway constriction after administration of nebulized albuterol.

Adults administer:

1. Ipratropium 500 mcg/2.5 mL NS nebulized

Used in the Following Protocols

Anaphylaxis/Allergic Reaction (Section 1 General Treatment)

Respiratory Distress (Section 3 Adult Treatment)